No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,201 | 1,719 | 2,329 | 2,876 | 3,304 | 3,625 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | 292 | 223 | 374 | 386 | 632 | 738 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Afya Limited, operating through its subsidiaries, is a prominent medical education provider in Brazil. The company delivers a comprehensive array of educational products and services primarily focused on the medical field, encompassing medical schools, preparatory courses for medical residency, advanced graduate studies, and various other programs tailored for medical professionals at all career stages. These offerings are available across its proprietary network and are also extended to external medical institutions. Beyond traditional education, Afya also offers digital health services through a subscription-based platform, accessible via a mobile app and website. This platform is specifically designed to assist healthcare practitioners and students with clinical decision-making by providing essential tools such as medical calculators, reference charts, up-to-date content, prescription guidance, clinical scoring systems, details on medical procedures, and laboratory examination information. While strong in medicine, Afya's educational portfolio spans a broader spectrum of health sciences, including dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine. Furthermore, the company extends its academic offerings beyond healthcare to include undergraduate and postgraduate degree programs in diverse subjects like business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. The company further enhances its educational ecosystem by providing specialized postgraduate medical programs, both printed and digital educational materials, an online medical learning platform, and hands-on medical training opportunities. As of December 31, 2021, Afya maintained an extensive network of 46 undergraduate and graduate medical school campuses, which included 30 operational undergraduate units and five approved units. This infrastructure supported a total capacity of 2,731 medical school seats, with 2,481 actively operating and an additional 278 seats approved for future use. Established in 1999, Afya Limited is headquartered in Nova Lima, Brazil.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Afya Limited, operating through its subsidiaries, is a prominent medical education provider in Brazil. The company delivers a comprehensive array of educational products and services primarily focused on the medical field, encompassing medical schools, preparatory courses for medical residency, advanced graduate studies, and various other programs tailored for medical professionals at all career stages. These offerings are available across its proprietary network and are also extended to external medical institutions. Beyond traditional education, Afya also offers digital health services through a subscription-based platform, accessible via a mobile app and website. This platform is specifically designed to assist healthcare practitioners and students with clinical decision-making by providing essential tools such as medical calculators, reference charts, up-to-date content, prescription guidance, clinical scoring systems, details on medical procedures, and laboratory examination information. While strong in medicine, Afya's educational portfolio spans a broader spectrum of health sciences, including dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine. Furthermore, the company extends its academic offerings beyond healthcare to include undergraduate and postgraduate degree programs in diverse subjects like business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. The company further enhances its educational ecosystem by providing specialized postgraduate medical programs, both printed and digital educational materials, an online medical learning platform, and hands-on medical training opportunities. As of December 31, 2021, Afya maintained an extensive network of 46 undergraduate and graduate medical school campuses, which included 30 operational undergraduate units and five approved units. This infrastructure supported a total capacity of 2,731 medical school seats, with 2,481 actively operating and an additional 278 seats approved for future use. Established in 1999, Afya Limited is headquartered in Nova Lima, Brazil.
